Skip to main content

Park, Emily


Dr. Emily Park joined the Bioengineering faculty at Santa Clara University as a lecturer in 2019, after 20 years of research and development experience in the biomedical industry. She is a molecular virologist by training with the emphasis on vaccine engineering and immune mechanisms. After academic training at the University of Massachusetts (Ph.D.) and the National Institute of Health (Postdoctoral), she’s continued her research in the biomedical industry. As a biomolecular engineer, she’s been leading the R&D functions in drug development, bioassays, and molecular diagnostics. Throughout her career in the industry, she’s been active members of the biomedical societies and produced numerous publications and patents.


Ph.D. University of Massachusetts

Courses Taught

Introduction to Physiology (BIOE 21)
Immune System for Engineers (BIOE 130)
Biomolecular Engineering II (BIOE 176)
Biotechnology I (BIOE 186)
Immunotherapy (BIOE 320)

Selected Publications

  1. Ray, T., E. Park, et al. 2019. Hidden mRNA isoforms diversify the cell-surface proteome in neural development and disease. Manuscript submitted
  2. Anderson, C., E. Park, et al. 2018. Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay. JoVE
  3. Baker, A-M., E. Park, et al. 2017. Robust RNA-based in situ mutation detection delineates colorectal cancer subclonal evolution. Nature Communications.
  4. Gulbahce, N., E. Park, et al. 2017. Quantitative whole-genome sequencing of circulating tumor cells enables personalized combination therapy of metastatic cancer. Cancer Research.
  5. Zhu, Y., E. Park, et al. 2017. Novel junction-specific and quantifiable in situ detection of AR-V7 and its clinical correlates in metastatic castration-resistant prostate cancer. European Urology
  6. Erben, L., E. Park, et al. 2017. A novel ultrasensitive in situ hybridization approach detects splice variants with cellular resolution. Biol. Psych.
  7. Mavropoulos, A., E. Park, et al. 2017. Simultaneous Detection of Protein and mRNA in Jurkat and KG-1a Cells by Mass Cytometry. Cytometry
  8. Ring, A., E. Park, et al. 2015. EpCAM Based Capture Detects and Recovers Circulating Tumor Cells From All Subtypes of Breast Cancer Except Claudin-low. Oncotarget.
  9. Van Hoof, D., W. Lomas, MB. Hanley, E. Park. 2014. Simultaneous flow cytometric analysis of IFN-γ and CD4 mRNA and protein expression kinetics in human peripheral blood mononuclear cells during activation. Cytometry
  10. Maino V., E. Park. 2013. Clinical implications of detecting low-abundance RNAs by flow cytometry. Expert Rev. Mol. Diagn.
  11. Hanley, MB., W. Lomas, D. Mittar, V. Maino, E. Park (senior author). 2013. Detection of Low Abundance RNA Molecules in Individual Cells by Flow Cytometry. PLOS ONE
  12. Guryev, O., E. Park, et al. 2011. Control of the fluorescence of dye-antibody conjugates by (2-hydroxypropyl)-β-cyclodextrin in fluorescence microscopy and flow cytometry. Analytical Chemistry
  13. Gao, F., E. Park, et al. 2009. Cross-Reactive Monoclonal Antibodies to Multiple HIV-1 Subtype and SIVcpz Envelope Glycoproteins. Virology.
  14. Nam, J-S., E. Park, J.K. Yoon et al. 2007. Mouse R-spondin2 is required for apical ectodermal ridge formation of the hindlimb by regulating Wnt/β-catenin signaling. Developmental Biol.
  15. Kim, K., E. Park, et al. 2005. Mitogenic Influence of Human R-Spondin 1 on the Intestinal Epithelium. Science
  16. Park, E., G.V. Quinnan, Jr. et al. 2000. A global neutralization resistance phenotype of HIV-1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex. J. Virol.
  17. Park, E., and G.V. Quinnan, Jr. 1999. Both Neutralization Resistance and High Infectivity Phenotypes Are Caused by Mutations of Interacting Residues in the Human Immunodeficiency Virus Type 1 gp41 Leucine Zipper and the gp120 Receptor- and Coreceptor-Binding Domains. J. Virol.
  18. Park, E., G.V. Quinnan, Jr. et al. 1998. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant HIV-1 MN to antibodies directed at V3 and non-V3 epitopes. J. Virol.
  19. Murphy, B.R., E. Park, et al. 1997. An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. Vaccine.
  20. Subbarao, E.K., E. Park, et al. 1995. Sequential addition of mutations to the PB2 gene of Influenza A PB2 transfectant viruses leads to increasing levels of temperature sensitivity and attenuation and permits the rational design of a genetically engineered influenza virus vaccine. J. Virol.
Park, Emily

Bioengineering Lecturer